NSAID Panel Could Give Naproxen Labeling Edge
This article was originally published in The Tan Sheet
Executive Summary
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.
You may also be interested in...
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.
OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel
Labels for over-the-counter NSAIDS need additional information about potential risks, panel members in a joint meeting of FDA’s Arthritis and Drug Safety and Risk Management advisory committees say. Data do not show naproxen has a lower CV thrombotic event risk compared to other NSAIDs, they say.